Gilead Sciences stock holds above $148 as revenue grows double digits
Published on 08/27/2026 at 10:04 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Gilead Sciences (US3755581036) stock traded around $148 per share as of August 26, 2026, supported by double-digit revenue growth and a steady dividend policy that continues to appeal to income-focused investors. Recent reporting highlights that the company has expanded quarterly revenue to $7.80 billion while maintaining a quarterly dividend of $0.82 per share, underscoring a combination of growth and cash returns that shapes the stock's current profile.
Market performance and valuation context
According to a recent market-data overview Gilead Sciences stock closed at $148.10 on August 26, 2026, with an intraday high of $149.62 and a low of $147.00, on volume of 5,233,952 shares. That closing level of $148.10 compares with an opening price of $148.00 on the same day, signaling a relatively tight intraday range around the current valuation. The same overview lists the trailing twelve-month revenue at $30.46 billion and EBITDA at $14.6 billion, framing the $148 handle in the context of a sizable and profitable business.
The stock's recent trajectory reflects a recovery from a prior slump, as another report notes that Gilead shares were trading around $130 per share ahead of a recent earnings release and have since moved to roughly $146 per share. This shift from $130 to $146 represents a gain of $16 per share, which equates to an increase of 12.3 percent, illustrating how the latest results and outlook have shifted sentiment. For investors, that move suggests that a portion of the upside from the latest catalysts may already be reflected in the current $148.10 closing price.
Latest earnings and cash-flow profile
Recent coverage of Gilead's latest quarter states that the company generated quarterly revenue of $7.80 billion, with the period described as a recent reporting quarter in 2026 that represents the most up to date financial snapshot available. The same report highlights that this $7.80 billion figure exceeded analyst expectations of $7.40 billion, implying a positive variance of $0.40 billion against consensus. In percentage terms, that revenue was up 10.6 percent compared with the same quarter a year earlier, underlining a double-digit top-line expansion.
On the profitability side, the company reported earnings per share of negative $6.75 in the latest quarter, a figure that nonetheless beat the average analyst estimate of negative $7.25 by $0.50 per share. This result came alongside a negative net margin of 10.64 percent and a negative return on equity of 2.11 percent, pointing to a period in which noncash or one-time items weigh on reported earnings even as revenue grows. Compared with the same quarter in the prior year, when Gilead delivered earnings per share of $2.01, the swing to a reported loss underscores how specific charges can reshape headline profitability from one year to the next even when revenue rises 10.6 percent.
Looking at the broader earnings picture, analyst projections cited in the same reports indicate that the company is expected to post full-year earnings per share of negative 0.5 for the current fiscal year. That expectation aligns with the latest quarterly loss of negative $6.75 per share and the negative net margin of 10.64 percent, suggesting that investors are weighing both the durability of the 10.6 percent revenue growth and the timeframe over which margins can normalize. For income-oriented shareholders, the key consideration is whether cash flow and balance sheet strength can support both ongoing investment and the dividend.
Dividend policy and shareholder returns
Gilead has reaffirmed its commitment to returning cash to shareholders through a regular dividend. Recent filings cited in financial commentary show that the company declared a quarterly dividend of $0.82 per share, which translates to an annualized payout of $3.28 per share. Based on the $148.10 closing price as of August 26, 2026, that $3.28 annual dividend corresponds to a forward yield of 2.2 percent, a level that can be attractive for investors seeking both income and exposure to the biopharmaceutical sector.
The same commentary notes that the dividend payout ratio is currently negative, reflecting the impact of the reported negative earnings per share and negative net margin. Specifically, the payout ratio is listed at negative 122.85 percent, indicating that the $3.28 annual dividend exceeds the recent accounting earnings base. For many large biopharmaceutical companies, such payout ratios during periods with unusual charges can be sustained if underlying cash flow remains strong, but investors will monitor how quickly earnings per share move back into positive territory to support the 2.2 percent yield longer term.
Historically, the company has balanced investment in research and development with shareholder returns, and the current combination of 10.6 percent revenue growth and a $0.82 quarterly dividend shows that management is continuing to deploy capital across both growth initiatives and cash distributions. If revenue continues to expand from the $7.80 billion quarterly level while cost structures normalize, the negative 10.64 percent net margin could move closer to the sector average, which in turn would improve earnings coverage of the dividend.
Analyst and institutional interest
Recent institutional activity highlights ongoing interest in the stock from professional investors. One cited report notes that a quantitative investment firm initiated a new stake in Gilead, emphasizing the company's position as a cash-flow generating business in an uncertain macroeconomic environment. That report grouped Gilead alongside two other companies described as cash-flow machines and pointed out that the firm generated $7.80 billion in quarterly revenue and maintained the $0.82 per share quarterly dividend, reinforcing the theme of stable cash returns.
Another institutional filing discussed in financial news described a large asset manager establishing a position valued at more than $150 million in Gilead shares. The piece again referenced the same set of metrics, including the $7.80 billion quarterly revenue figure, the $7.40 billion consensus estimate, and the negative $6.75 earnings per share result. For investors, these filings serve as evidence that despite accounting losses, the combination of 10.6 percent revenue growth and a 2.2 percent dividend yield remains attractive enough to draw sizable institutional capital.
It is also noted in these analyses that revenue in the latest quarter rose 10.6 percent year over year, compared with a prior-year quarterly revenue level that implied single-digit growth before the latest acceleration. The step up to 10.6 percent growth, combined with the earnings per share beat of $0.50 versus expectations, has been cited as a central reason why the stock price moved from around $130 ahead of earnings to around $146 afterward. This quantified link between fundamentals and price helps explain why institutional investors have been willing to increase exposure at current levels.
Investor conferences and communication plans
Gilead has also outlined its plans to engage with the investment community through upcoming appearances at investor conferences in the third quarter of 2026. An announcement published from the company's headquarters in Foster City, California, stated that Gilead will present at several investor conferences during the third quarter of 2026, giving management an opportunity to discuss recent performance and strategic priorities. These events typically allow executives to elaborate on revenue trends, pipeline progress, and capital allocation, including the ongoing $0.82 quarterly dividend.
The investor conference announcement did not specify new financial guidance, but such events often provide color on how management views the sustainability of the recent 10.6 percent revenue growth and the path toward restoring positive net margins following the negative 10.64 percent figure in the latest quarter. For shareholders, the fact that the stock has held at a $148.10 closing price as of August 26, 2026 while management prepares to speak at multiple conferences suggests that the market is looking for confirmation that recent growth can be maintained.
As these conferences approach, analysts will likely refine their models based on any new commentary, particularly regarding the earnings outlook where the current full-year forecast stands at negative 0.5 earnings per share. A shift toward a more positive earnings trajectory, while maintaining or growing revenue beyond the $7.80 billion quarterly level, could support a re-rating of the shares from the $148 region if the market becomes more confident that the negative net margin and negative return on equity are temporary.
Key therapies and business model
Gilead's business centers on antiviral and oncology therapies, with a portfolio that includes treatments for HIV, hepatitis, and other serious diseases. One representative product from its antiviral franchise is a once-daily oral therapy that has become a core component of modern HIV treatment regimens. This therapy contributes to the company's substantial trailing twelve-month revenue of $30.46 billion and underpins its status as a major player in infectious disease treatment.
The company's model combines long-established therapies with newer pipeline assets, and the latest quarterly revenue of $7.80 billion reflects contributions from both mature and emerging products. As revenue grew 10.6 percent year over year in the most recent quarter, investors infer that newer therapies and indications are beginning to offset pricing and volume pressures in older franchises. The ability to sustain and build on that 10.6 percent growth rate is central to the investment case, given that earnings per share temporarily dipped to negative $6.75 due to specific charges.
Beyond antivirals, Gilead continues to invest in oncology, inflammatory diseases, and other areas where it sees potential for differentiated therapies. These investments are funded from a combination of operating cash flow, which is consistent with the $14.6 billion trailing twelve-month EBITDA figure, and balance sheet resources. The company's capacity to generate EBITDA at that scale, coupled with a trailing twelve-month revenue base of $30.46 billion, provides a foundation for continued research and development while also sustaining the current $0.82 per share quarterly dividend.
Stock snapshot and investor takeaway
As of the close on August 26, 2026, Gilead Sciences stock traded at $148.10 on Nasdaq under the ticker GILD, with a trailing twelve-month revenue base of $30.46 billion and EBITDA of $14.6 billion supporting its valuation. The latest reported quarter delivered revenue of $7.80 billion, which exceeded the $7.40 billion consensus estimate and represented 10.6 percent year-over-year growth, even as earnings per share registered negative $6.75 with a negative net margin of 10.64 percent. For investors, the combination of a stable $3.28 annual dividend, equivalent to a 2.2 percent yield at $148.10, and double-digit revenue growth frames the stock as a balance between income and growth characteristics.
Go deeper
Flagship HIV therapy as a pillar
Within Gilead's portfolio, its flagship HIV therapy line continues to serve as a cornerstone of revenue and strategic positioning. These once-daily regimens have helped modernize HIV care by simplifying dosing and improving adherence, contributing significantly to the company's $30.46 billion in trailing twelve-month revenue. The continued uptake of these therapies supports the 10.6 percent quarterly revenue growth that lifted the latest period's sales to $7.80 billion, even as other parts of the portfolio face competitive and pricing pressures.
The HIV franchise also illustrates how Gilead balances innovation and lifecycle management. As patents on older therapies expire, the company introduces next-generation regimens that offer improved safety or efficacy profiles, helping to sustain revenue in key markets. This approach, combined with expansion into new indications and geographies, is a major reason why the latest quarterly revenue could grow 10.6 percent year over year despite a challenging macroeconomic backdrop. For investors, the HIV business serves as both a cash generator and a platform for future innovation that can support dividends and pipeline investment.
Current price and market positioning
Gilead Sciences stock closed at $148.10 on August 26, 2026, on Nasdaq, with intraday trading spanning a range from $147.00 to $149.62 and volume of 5,233,952 shares. At that price, the annual dividend of $3.28 per share implies a yield of 2.2 percent, aligning the stock with other large-cap biopharmaceutical names that combine income and growth features. The recent move from $130 ahead of earnings to around $146 afterward, and the subsequent close at $148.10, indicates that the market has already repriced the shares to reflect the 10.6 percent revenue growth and the earnings per share beat of $0.50 versus expectations.
Fact box
Company: Gilead Sciences, Inc.
ISIN: US3755581036
Ticker: GILD
Exchange: Nasdaq
Price (as of August 26, 2026, 4:00 p.m. ET): $148.10 USD
Market cap: Data not specified in available sources
Sector / Industry: Biotechnology / Biopharmaceuticals
Index membership: S&P 500
